Omnicell Com Stock Price, News & Analysis

Omnicell has acquired ReCept Holdings for $100 million, enhancing its Advanced Services portfolio in specialty pharmacy management. The acquisition is projected to boost Omnicell's non-GAAP EBITDA starting Q1 2023, aligning with its strategy to address the complex specialty pharmacy market. ReCept reported annual recurring revenue of $24 million as of September 30, 2021. This addition allows Omnicell to optimize specialty pharmacy programs and improve patient care, further solidifying its position in medication management solutions.

Omnicell announced its strategic acquisition of ReCept Holdings for $100 million, aiming to enhance its Advanced Services portfolio. This acquisition responds to the growing need for effective management of complex medications, which represent over 50% of the U.S. drug spending. ReCept's capabilities in specialty pharmacy management will support Omnicell's vision of an Autonomous Pharmacy. This transaction is expected to close by year-end 2022 and will be accretive to Omnicell's non-GAAP EBITDA in Q1 2023.

Omnicell, Inc. (NASDAQ: OMCL) announced its participation in two upcoming investor conferences. Randall Lipps, Chairman and CEO, along with Scott Seidelmann, Executive VP, will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1, 2021, at 9:00 am ET. Additionally, Peter Kuipers, Executive VP and CFO, will appear at the 2021 Stephens Annual Investment Conference on December 3, 2021, at 10:00 am CT in Nashville, TN. Webcasts of both presentations will be accessible on the Omnicell website.

Omnicell, Inc. (NASDAQ:OMCL) is collaborating with Fresenius Kabi to enhance pharmacy technology in U.S. hospitals. Their partnership introduces the Controlled Substance Dispenser (CSD), targeting improved management of controlled substances and increased efficiency in medication dispensing. This innovation aims to mitigate the significant loss of medication—over 148 million doses in 2019—which affects patient and workforce safety. The newly designed cassettes for Omnicell's CSD support Fresenius Kabi's MicroVault prefilled syringes, streamlining processes for healthcare providers.

Omnicell (NASDAQ: OMCL) announced the Tucson VA Medical Center as the first Veterans Affairs facility to implement its Central Pharmacy Dispensing Service (CPDS). This initiative aims to enhance patient safety, increase operational efficiency, and optimize inventory management in pharmacy operations. The partnership highlights Omnicell's commitment to transforming pharmacy care delivery through automation and technology, supporting the Veterans Health Administration's mission to serve 9 million veterans annually.

Omnicell reported Q3 2021 revenues of $296 million, a 38.7% year-over-year increase, with net income of $29 million or $0.61 per share. For the nine months, total revenues reached $821 million, up 27.7%. Non-GAAP results showed similar trends with net income of $49.9 million or $1.08 per diluted share. The company expects Q4 2021 revenues between $308-313 million, driven by strong commercial momentum and the acquisition of FDS Amplicare, which enhances its SaaS offerings for pharmacies.

Omnicell, Inc. (NASDAQ: OMCL) will report its third-quarter 2021 financial results on November 2, 2021, before market open. A conference call is scheduled for 8:30 a.m. ET the same day to discuss these results. As a leader in medication management solutions, Omnicell aims to enhance pharmacy care delivery through automation and technology. The company has over 7,000 facilities utilizing its solutions to improve operational efficiency, patient safety, and adherence to prescriptions.

On October 6, 2021, FDS Amplicare announced a webinar aimed at helping pharmacists assist patients in selecting appropriate Medicare plans during the open enrollment period from October 15 to December 7. Hosted by Nathan Shanor, the webinar emphasizes utilizing online tools and collaboration with licensed insurance agents to ease the enrollment process. FDS Amplicare, recently acquired by Omnicell (OMCL), enhances pharmacists' capabilities with its Match solution, empowering them to provide informed plan choices to seniors. For more details, visit FDS Amplicare's website.

Omnicell has announced the acquisition of FDS Amplicare for $177 million, enhancing its EnlivenHealth division with advanced SaaS financial management and analytics solutions. This acquisition integrates FDS Amplicare's tools into Omnicell's offerings, aimed at reducing DIR fees for retail pharmacies. The deal is expected to be immediately accretive to Omnicell's non-GAAP EBITDA and earnings per share, leveraging a network of over 15,000 independent pharmacies.